Integra LifeSciences (IART) Tops Q2 EPS by 1c; Updates FY11 Outlook, Revs Above Street
Tweet
Share
E-mailGet Alerts IART Hot Sheet
Join SI Premium – FREE
Integra LifeSciences Holdings (NASDAQ: IART) reported Q2 EPS of $0.70, $0.01 better than the analyst estimate of $0.69. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $188.78 million.
Integra LifeSciences Holdings sees FY2011 EPS of $2.92-$3.02, versus the consensus of $2.98. Integra LifeSciences Holdings sees FY2011 revenue of $785-$800 million, versus the consensus of $783.55 million.
Integra LifeSciences Holdings sees FY2011 EPS of $2.92-$3.02, versus the consensus of $2.98. Integra LifeSciences Holdings sees FY2011 revenue of $785-$800 million, versus the consensus of $783.55 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Integra LifeSciences Announces Key Executive Appointments
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Worthington Industries (WOR) Misses Q4 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
